Tạp chí Tim mạch học Việt Nam

Chi tiết bài viết

Mô tả chi tiết bài viết

Trang chủ
CHUYÊN ĐỀ Số phát hành: Số 69 - 2015

Bóng phủ thuốc: Tiếp cận mới trong điều trị tái hẹp lại trong Stent

Xuất bản: tháng 3 31, 2015
Views: 778

Tóm tắt

Bóng phủ thuốc: Tiếp cận mới trong điều trị tái hẹp lại trong Stent

Tài liệu tham khảo

1.
1. King SB, Schlumpf M. Ten year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experiance. J Am Coll Cardiol 1993; 22: 353-360.
2.
2. Sigwart U., Puel J., Mirkovitch V., Joffre F., Kappenberger L., Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Eng J Med 1987; 316: 701-706.
3.
3. Dangas GD., Claessen BE., Caixeta A., Sanidas EA., Mintz GS., Mehran R., In-stent restenosis in the drug- eluting stent era. J Am Coll Cardiol 2010: 56: 1897-1907.
4.
4. Chen MS., John JM., Chew DP., Lee DS., Ellis SG., Bhatt DL., Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006; 151: 1260-1264.
5.
5. Bossi I., Klersy C., Black AJ. Et al., In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35: 1569-1576.
6.
6. Strikwerda S., Montauban van Swijindregt E., Foley DP., et al., Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions. J Am Coll Cardiol 1995; 26: 939-46.
7.
7. Hehrlein C., DeVries JJ., Arab A., et al., Failure of a novel balloon - expandable gamma-emitting((103)Pd) stent to prevent edge effects. Circulation 2001;104: 2358-2362.
8.
8. Albiero R., Adamian M., Kobayashi N., et al. Short and intermediate term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: the Milan Dose-Response
9.
Study. Circulation 2000; 101: 18-26.
10.
9. Alfonso F., Perez-Vizcayno MJ., Dutary J., et al., Implantation of a drug-eluting stent with a different drug (switch straegy) in patients with drug-eluting stent restenosis. Results from a prospectivemulticenter study (RIBS III [ Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). J Am Coll Cardiol Intv 2012;5: 728-737.
11.
10. Lemos PA., Hoye A., Goedhart D.,et al. Clinical, angiographic, and precodural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109: 1366-1370.
12.
11. Herdeg C., Oberhoff M., Baumbach A.,et al., Local paclitaxel delivery for the prevention of restenosis: biological efects and efficacy in vivo. L AM Coll Cardiol 2000: 35: 1969-1976.
13.
12. Axel DI., Kunert W., Goggelmann C., et al., Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
14.
13. Werk M., Langner S., Reinkensmeier B., et al. Inhibitation of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized lipot trial. Circulation 2008; 118: 1358-1365.
15.
14. Scheller B., Hehrlein C., Bocksch W., et al. Treament of coronary in-stent restenosis with a paclitaxel- coated balloon catheter. N Engl J Med. 2006; 355: 2113-2124.
16.
15. Habara S., Mitsudo K., Kadota K., et al., Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. J Am Coll Cardiol Intv 2011; 4: 149-154.
17.
16. Rittger H., Brachmann J., Sinha AM., et al. A randomized, multicenter, single-blinede trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES sudy. J Am Coll Cardiol 2012; 59: 1377-1382.
18.
17. Byrne RA., Neumann FJ., Mehilli J., et al., Paclitaxxel balloons, paclitaxel-eluting stents, and balloon angiplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013; 381:461-467.
19.
18. Indermuehle A., Bahl R., Lansky Ạ., et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart 2013;99: 327-333.
20.
19. Agostoni P., Belkacemi A., Voskuil M., Nathoe HM., Doevendans PA., Stella PR., Serial morphological and functional assessment of drug-eluting balloon for in-stent restenosis lesions: mechanisms of action evaluted with angioplasty, optical coherence tomography and fractional flow reserve. J Am Coll Cardiol Intv 2013; 6: 569-576.
21.
20. Mehilli J., Byme RA., Tiroch K., et al. Randomized trial of paclitaxel versus sirolimus-eluting stents for treament of coronary restenosis in sirolimus-eluting stents: ISAR-DESIRE 2 ( Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010; 55: 2710-2716.
22.
21. Wijins W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.

Tác giả

Nguyễn Minh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai; Phạm Mạnh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Bóng phủ thuốc: Tiếp cận mới trong điều trị tái hẹp lại trong Stent

Tệp

Lượt xem bài778
Lượt xem tài liệu0
Lượt tải xuống15
Chuyên mục CHUYÊN ĐỀ
Số phát hành Số 69 - 2015
Trang 142-145
Chủ sở hữu bản quyền 2015 Tạp chí Tim mạch học Việt Nam